Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control As a Means of Improving Glycemic Control in Adults with Type 2 Diabetes Mellitus
NCT ID: NCT04595968
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
267 participants
INTERVENTIONAL
2021-05-21
2024-08-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to evaluate the efficacy of non-invasive electrical vestibular nerve stimulation (VeNS), together with a lifestyle modification program, as a method of reducing HbA1c, as compared to a sham control.
Allocation: Randomized to either active device or control device usage. All subjects will receive the same lifestyle advice.
Endpoint classification: Efficacy Study Intervention Model: Parallel Assignment in 1:1 active to control allocation Trial Participants: Those who have been diagnosed with Type 2 diabetes mellitus.
Planned Trial Period: The study will last 24 weeks in total for each subject. The primary analysis will be conducted at the 24 weeks timepoint.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control as a Means of Reducing Excess Body Weight
NCT04110717
Efficacy of Electrical Vestibular Nerve Stimulation (VeNS) in the Management of Obesity: A Randomized Clinical Trial
NCT05275790
Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Anxiety: A Randomized Clinical Trial
NCT05845658
Noninvasive Vagus Nerve Stimulation (VNS) for Neuromotor Adaptations
NCT03628976
Effect Of Percutaneous Electrical Nerve Field Stimulation on Symptom Control/Nervous System Activity in Patients w/Diabetes Types 1/2
NCT06783504
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vestal DM active device
150 subjects randomised to receive active device plus lifestyle intervention for 24 weeks
Vestal DM Active device
Battery powered non-invasive neurostimulation device
Lifestyle modification
Subjects are prescribed a low calorie (500kcal deficit) diet if their BMI is ≥25. If a subject has a BMI of ≤24.9, they will be provided with guidance on ensuring their recommended daily dietary intake is achieved throughout the course of the trial (i.e 2,500kcal/day for men and 2,000kcal/day for women)
Vestal DM sham device
150 subjects randomised to receive sham device plus lifestyle intervention for 24 weeks.
Lifestyle modification
Subjects are prescribed a low calorie (500kcal deficit) diet if their BMI is ≥25. If a subject has a BMI of ≤24.9, they will be provided with guidance on ensuring their recommended daily dietary intake is achieved throughout the course of the trial (i.e 2,500kcal/day for men and 2,000kcal/day for women)
Vestal DM Sham device
Placebo comparator sham device (no active stimulation)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vestal DM Active device
Battery powered non-invasive neurostimulation device
Lifestyle modification
Subjects are prescribed a low calorie (500kcal deficit) diet if their BMI is ≥25. If a subject has a BMI of ≤24.9, they will be provided with guidance on ensuring their recommended daily dietary intake is achieved throughout the course of the trial (i.e 2,500kcal/day for men and 2,000kcal/day for women)
Vestal DM Sham device
Placebo comparator sham device (no active stimulation)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female, age ≥ 22 years and ≤ 70 years at the time of signing informed consent. (At the US sites). The non-US sites will recruit subjects aged ≥ 18 and ≤ 70 years.
* Diagnosed with Type 2 DM ≥ 90 days prior to day of enrolment
* HbA1c (glycated hemoglobin) ≥ 6.5 and ≤ 9.5% (48-80 mmol/mol) (both inclusive).
* If taking medication to treat diabetes, a stable dose of no more than 3 anti-diabetic medications for at least 90 days prior to enrolment.
* BMI ≥ 25 at non-US sites
* Must be under care of physician for follow-up of their type 2 DM (this can be a Primary Care Physician (PCP), endocrinologist or other hospitalist).
* Must agree to continue to participate with their routine diabetes care program.
* Access to Wi-Fi.
Exclusion Criteria
* Diagnosis of diabetic neuropathy
* Diagnosis of diabetic nephropathy
* Diagnosis of retinopathy
* Skin breakdown, eczema or other dermatological condition (e.g. psoriasis) affecting the skin behind the ears. Any disorder which in the investigator's opinion might jeopardize subject's safety or compliance with the protocol.
* Taking beta-blockers (if previously then can enroll if off ≥ 30 days).
* Taking insulin (if previously on insulin then should be off for ≥ 90 days prior to enrolment).
* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice)
* History of pancreatitis
* History of pancreatic surgery
* Hemochromatosis
* Either of the following within the previous year: myocardial infarction; or acute coronary syndrome.
* History of stroke
* History of epilepsy
* Splenectomy (due to effect on red blood cell turnover)
* History of anemia (if resolved for \> 90 days with treatment then can enroll)
* Blood transfusion within 90 days of enrolment (due to effect on HbA1c). (If transfusion occurs once enrolled then subject will be withdrawn).
* A diagnosis of a hemoglobinopathy (e.g. sickle cell disease and thalassemia, although those with sickle cell or thalassemic trait would be allowed to enroll);
* If on dietary supplements or herbal remedies, then if the subject is taking a preparation that might affect glycemic control they will be excluded. Specifically, subject will be excluded if taking biotin (vitamin B7); alpha-lipoic acid; chromium; herbal preparations marketed as being for diabetes.
* History of being diagnosed with renal, heart or liver failure
* History of active migraines with aura
* History of head injury requiring intensive care or neurosurgery.
* Change in diabetic medication within the last 90 days (prior to enrolment).
* Regular use (more than twice a month) of antihistamine medication within the last 6 months. Note: If the participant is taking Fexofenadine, they can be eligible for the trial. If the participant is on another anti-histamine medication they can voluntarily opt to switch to Fexofenadine and enrol in the trial after a washout period of 2 weeks.
* Current use of H2-receptior antagonist medication? (e.g., cimetidine, famotidine)
* History or presence of malignancy within the last year (except basal and squamous cell skin cancer and in-situ carcinomas)
* A diagnosis of myelofibrosis or a myelodysplastic syndrome.
* Previous use of Modius device
* Participation in other clinical trials sponsored by Neurovalens (e.g. Vestal study)
* Presence of permanently implanted battery powered medical device or stimulator (e.g., pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve stimulator etc.)
* Have a member of the same household who is currently participating in this study.
* History of vestibular dysfunction or other inner ear disease (as assessed on the screening questionnaire)
* Failure to pass the ATMAS Flex hearing test
* Failure to demonstrate a willingness for lifestyle modification (i.e diet and exercise) if BMI is ≥25 (as assessed on the screening questionnaire)
* Failure to agree to weekly engagements with the Clinical Trial Mentors during trial participation
* Failure to agree to use of device daily during trial participation (no more than 2 weeks usage drop without reasonable explanation)
* Use of any medication (e.g. hormonal modulators or corticosteroids) that could cause iatrogenic T2DM. (NB Topical steroid use is acceptable if judged by PI to be unrelated).
* Any other medical condition, or medication use, that in the opinion of the PI/CI is likely to make the subject refractory to VeNS.
22 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University College Dublin
OTHER
CS Lifescience
UNKNOWN
Clinical Trial Mentors
INDUSTRY
Neurovalens Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erik Viirre, MD PhD
Role: PRINCIPAL_INVESTIGATOR
UC San Diego
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama
Birmingham, Alabama, United States
UC San Diego, Exercise and Physical Activity Resource Center
La Jolla, California, United States
Northern California Research
Sacramento, California, United States
New Med Research
Hollywood, Florida, United States
South Florida Research Organization
Medley, Florida, United States
Adult Medicine of Lake County
Mt. Dora, Florida, United States
Oviedo Medical Research
Oviedo, Florida, United States
ActivMed Practices & Research
Methuen, Massachusetts, United States
Billings Clinic
Billings, Montana, United States
Palm Research Center
Las Vegas, Nevada, United States
ActivMed Practices & Research
Portsmouth, New Hampshire, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Complete Health Partners
Nashville, Tennessee, United States
Biopharma Informatic
McAllen, Texas, United States
Charlottesville Medical Research Center
Charlottesville, Virginia, United States
St. Vincent's University Hospital
Dublin, Dublin, Ireland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VeSTALDM01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.